Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Article excerpt
Highlighted: the sentence this signal was extracted from
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi's decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today's announcement does not change Nurix's recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029. "While today's news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline," said Arthur T. Sands, M.D., Ph.D., president and...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.